Insulin icodec
Highest phase reached
Approved
Drug type
Protein
First approval year
2024
- First approval year
- 2024
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Protein
- Drug name
- Insulin icodec
- awiqli
- Awiqli
- insulin icodec component of nn1535 icosema
- Insulin icodec component of nn1535 icosema
- insulin icodec component of nn1535 laisema
- Insulin icodec component of nn1535 laisema
- insulin 287
- Insulin 287
- insulin icodec
- Insulin icodec
- Insulin Icodec
- insulin icodec [INN]
- INSULIN ICODEC [USAN]
- Insulin icodec [WHO-DD]
- insulin icodec abae
- Insulin icodec Injection
- Insulin Icodec Injection
- insulin icodec inn
- insulin icodec usan
- insulin icodec who dd
- Insulin Icodec-ABAE
- long acting insulin 287
- Long-acting-insulin-287
- nn1436
- NN1436
- nn1535 icosema component insulin icodec
- NN1535 ICOSEMA COMPONENT INSULIN ICODEC
- nn1535 laisema component insulin icodec
- NN1535 LAISEMA COMPONENT INSULIN ICODEC
- nnc0148 0287
- Nnc0148-0287
And 3 more, listed on the interactive page.
- ATC classification codes
- A10AE07
Sources for recorded values
- CAS registry numbers
- 1188379-43-2
- ChEMBL ID
- CHEMBL4594581
- RxNorm IDs (RxCUI)
- 2740394
- FDA ingredient codes (UNII)
- P7YU3ED05N
- Applicant
- NOVO NORDISK INC
- Approval date
- 26 Mar 2026
- Application number
- BLA761326
- Status
- Authorised
- Status date
- 17 May 2024
- Authorisation date
- 17 May 2024
- Approved indications
- Treatment of diabetes mellitus in adults
- Product number
- EMEA/H/C/005978
- Authorisation holder
- Novo Nordisk A/S
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
European medicines record
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Insulin receptor agonist
- Action type
- Agonist
- Target
- Insulin receptor
- Protein identifier
- P06213
Open Targets mechanisms
- Mechanism
- Insulin receptor agonist
- Action type
- Agonist
- Target
- Insulin receptor
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Diabetes Mellitus, Type 1
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005147
- Subject identifier
- D003922
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- EFO_0000400
- Condition identifier
- MONDO_0005015
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005147
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005148
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 4
Trial references
- NCT03789578
- Dose
- 70 units
- Route
- Subcutaneous
- How often
- Once weekly
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Disulfide bridges
- Sequence
- 6-11 $ 7-7 $ 20-19
- Component
- Sequence: Alpha chain
- Type
- Protein
- Sequence
- GIVEQCCTSICSLEQLENYCN
- Component
- Sequence: Beta chain
- Type
- Protein
- Sequence
- FVNQHLCGSHLVEALHLVCGERGFHYTPK
Related records
Trials (38)
- A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males
- A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
- A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
- A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems
- A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week
- A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week
- A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
- A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
- A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
- A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
- A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
- A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
- A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
- A Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec
- A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together
- A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together
- A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
- A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Approved for (3)
- Diabetes mellitus
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Targets (1)
- INSR Insulin receptor agonist